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A multicenter experience evaluating chronic total
occlusion crossing with the Wildcat catheter (the
CONNECT study)
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Objective: Percutaneous techniques for crossing femoropopliteal chronic total occlusions (CTOs) offer an alternative to
bypass surgery in patients deemed to be at increased risk due to advanced age or comorbidities. Recent reports document
good success rates in catheters designed to reconstitute peripherally occluded arteries following failed guidewire passage.
The Wildcat catheter (Avinger, Redwood City, Calif) is a novel device with a rotating distal tip and deployable wedges
fashioned for channeling a passage through arterial occlusions. This report describes the results of a prospective,
multicenter, nonrandomized trial evaluating the safety and efficacy of the Wildcat device when crossing de novo or
restenotic femoropopliteal CTOs.
Methods: Between August 2010 andApril 2011, patients with peripheral arterial disease due to a femoropopliteal CTO>1 cm
and<35 cmwere evaluated for study enrollment at 15 U.S. sites. During treatment, the physician initially attempted to cross
the CTOusing conventional guidewires per protocol; if the guidewire successfully crossed, the patient was considered a screen
failure and theWildcat was not deployed. At 30 days, patients were reevaluated. The primary efficacy end point was successful
crossing of the Wildcat into the distal true lumen as confirmed by angiography. Primary safety end points included no
in-hospital or 30-day major adverse events, no clinically significant perforation or embolization, and no grade C or greater
dissection. Additional data collected included lesion length, degree of calcification, and location.
Results: Eighty-eight patients were enrolled in the trial. Of these, the Wildcat device was used in 84 patients (95%) per
protocol. Successful CTO crossing was reported and confirmed by independent review in 89% (75/84) of cases with 5%
(4/84) major adverse events as defined in the protocol (predominantly perforations sealed with balloon inflation). There
were no clinically relevant events associated with any of the perforations. Themean CTO length was 174 96mm (range,
15-350 mm). Approximately 57% (n  48) of all lesions were categorized as containing at least moderate calcification.
Eighty-nine percent (n  75) of vessels recanalized were superficial femoral arteries.
Conclusions: In this multicenter study, the Wildcat catheter demonstrated an 89% crossing success rate with little
associated morbidity. The Wildcat catheter is a viable device for crossing moderately calcified femoropopliteal CTOs.
(J Vasc Surg 2012;56:1615-21.)
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aThe treatment of chronic total occlusions (CTOs) in
patients with infrainguinal peripheral arterial disease (PAD)
remains a particularly challenging endeavor for vascular
specialists. Historically, surgical revascularization has been
the gold standard for treatment of CTOs, but intervention-
alists increasingly choose an endovascular approach because
of the increased age and complex medical comorbidities of
these patients.1,2 Moreover, many patients prefer endovas-
cular treatment due to its reduced cost, shorter hospital
stay, and reduced procedural morbidity.
From the Jobst Vascular Institute, Toledoa; the El Paso Cardiology Associ-
ates, El Pasob; and the St. John Hospital and Medical Center, Detroit.c
Author conflict of interest: Drs Pigott and Davis have been paid a consulting
fee by and are shareholders in Avinger.
Presented at the Thirty-fifth Annual Meeting of the Midwestern Vascular
Surgery Society Annual Meeting, Chicago, Ill, September 15-17, 2011.
Reprint requests: John P. Pigott, MD, Jobst Vascular Institute, 2109
Hughes Dr, Ste 400, Toledo, OH 43606 (e-mail: marilyn.gravett@
promedica.org).
The editors and reviewers of this article have no relevant financial relation-
ships to disclose per the JVS policy that requires reviewers to decline
review of any manuscript for which they may have a conflict of interest.
0741-5214/$36.00(
Copyright © 2012 by the Society for Vascular Surgery.
http://dx.doi.org/10.1016/j.jvs.2012.06.071Until recently, the most common way to cross femoro-
opliteal CTOs was to choose either an intraluminal or sub-
ntimal approach. The fallback position for failed initial guide-
ire crossing of the CTO intraluminally was subintimal
ngioplasty, a technique originally popularized by Bolia et al3
nd subsequently validated by others.4-6 Both intraluminal
nd subintimal techniques have their proponents, usually
ased on training and personal experience. However, there is
ittle comparative data evaluating these approaches. More-
ver, in the scenario of a long fibrotic and calcified CTO, an
ntraluminal crossing attempt with a conventional guidewire
ay be impossible, forcing the specialist to switch to a subin-
imal approach to achieve success.
The recent introduction of specially designed cross-
ng catheters may improve crossing rates, thereby allow-
ng a more rapid delivery of therapeutic devices to the
arget lesion, reduced crossing times, and more uniform
istal reentry. These devices employ various technolo-
ies for tunneling through the CTO, including blunt
icrodissection, vibrational energy, lasers, optical coher-
nce reflectometry, and intravascular ultrasound imaging
IVUS).7-14 One of the most recent crossing catheters
pproved by the U.S. Food and Drug Administration
FDA) is the Wildcat catheter (Avinger, Redwood City,
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December 20121616 Pigott et alCalif), a device that employs rotatable spiral wedges in
the distal tip to provide both active and passive configu-
rations. This paper reports the results of a prospective,
multicenter study designed to evaluate safety and efficacy
end points of the Wildcat for crossing de novo or rest-
enotic femoropopliteal CTOs.
METHODS
Aprospective,multicenter, nonrandomized trial, Chronic
Total Occlusion Crossing with the Wildcat Catheter
(CONNECT), was performed to evaluate the safety and
efficacy of the Wildcat device in crossing a single femoropop-
litealCTO.ThisU.S. InvestigationalDeviceExemption study
enrolled patients at 15 clinical sites in the U.S. and was
approved by each site’s institutional review board. Prior to
enrollment, informed consent was obtained from each pa-
tient.
Study design. Patients presenting with PAD requir-
ing revascularization, evidenced by computed tomography
or magnetic resonance angiography, were eligible for en-
rollment in the study. Final eligibility was confirmed once
the subject completed informed consent, and an angiogram
of the diseased peripheral segment confirmed the presence
of a femoropopliteal artery that was 99% to 100% stenosed
with a length 1 cm and 35 cm by visual estimate and a
diameter3.0 mm. Table I lists all inclusion and exclusion
criteria.
Upon enrollment, patients underwent a baseline eval-
uation that encompassed history and physical examination,
medication review, laboratory tests per precatheterization
interventional procedures, ankle-brachial index (ABI), and
Rutherford classification of lower extremity disease. Post-
intervention, study patients underwent follow-up at 30
days (5 days), which consisted of an adverse event assess-
ment, ABI, and Rutherford classification assessment.
All study data were collected and recorded on case
report forms. Procedural site reporting was independently
verified by two board-certified radiologists trained for an-
giographic review and who had no affiliation with Avinger
or the CONNECT study. Both reviewers recorded their
analyses on case report forms tabulated for both primary
and safety end points, and a third independent radiologist
was consulted to resolve any discrepancies.
Study end points and definitions. The primary effi-
Table I. Inclusion/exclusion criteria
Inclusion
Patient is 18 years old
Peripheral arterial disease requiring revascularization as evidenced
contrast, computed tomography, or magnetic resonance
angiography
Occluded femoropopliteal artery (99%-100% stenosed) and is 1
cm and 30 cm in length
Target femoropopliteal vessel is 3.0 mm in diameter
Rutherford classification of 2-5cacy end point of this study was to assess crossing success eith the Wildcat device by angiographic confirmation of
uidewire placement in the distal true lumen. Primary
afety end points included in-hospital or 30-day major
dverse events (MAEs), clinically significant perforation, or
mbolization and grade C dissection. Secondary end points
ncluded device, lesion, and procedure success, procedure
afety, procedural and fluoroscopic times, and contrast
olume. In addition, other important modifiers to be im-
ged and recorded included calcific burden, lesion shape,
ocation, and distal run-off vessels.
The following study end point definitions were ap-
roved by the U.S. FDA prior to the commencement of the
tudy: (1) MAEs were defined as death, unplanned target
imb major amputation, and emergent target vessel revas-
ularization; (2) clinically significant perforations were de-
ned as all perforations requiring intervention (eg, angio-
lasty, covered stent, bypass, or other); (3) clinically
ignificant embolization was defined as those events that
esult in distal ischemia (eg, occlusion of run-off vessel
esulting in pain or foot discoloration) and/or require
escue intervention; (4) grade C dissection was defined as
ig 1. The tip of the Wildcat catheter can be configured in both
assive (top) and active (bottom) modes.
Exclusion
Target vessel is severely calcified as evidenced by angiography
Target lesion is in a bypass graft
Target lesion is in a stent (ie, in-stent restenosis)
Prior procedure on the target limb within the past 30 days
Planned surgical or interventional procedure within 30 days
after the study procedurebyxtraluminal, persisting extravasation of contrast; (5) de-
dhaft,
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Volume 56, Number 6 Pigott et al 1617vice success was defined as successful delivery, crossing, and
retrieval of the investigational device; (6) lesion success was
defined as attainment of50% final residual stenosis of the
target lesion using any percutaneous method; and (7)
procedure success was defined as device success in the
absence of in-hospital MAEs.
Device description. The Wildcat catheter is designed
to traverse CTOs through the use of bilateral wedges
contained within the distal tip of the device (Fig 1). The
Wildcat consists of the distal tip, catheter shaft, and proxi-
mal handle that allows for device manipulation and a means
for flushing the catheter lumen (Fig 2). The catheter is 6F
compatible, 110 cm long, and intended for use with 0.035”
guidewires. Wedge elements located in the distal tip rotate
both clockwise and counterclockwise and are visible under
fluoroscopy.
The tip has both passive and active configurations
(Fig 1). The active configuration is a more aggressive tip
profile that occurs when the spiral wedges are exposed
out of the catheter tip by sliding the hand control to
advance them. If a standard interventional technique
does not allow for wire crossing of a CTO, the Wildcat is
delivered and engaged in the proximal cap. The tip is
rotated in the counterclockwise passive mode first. If the
cap is not traversed, the clockwise active mode is config-
ured. The tip is rotated until the proximal cap is pene-
trated and channeling through the CTO is initiated.
Reentry into the distal patent reconstituted vessel is
confirmed by guidewire advancement and/or contrast
injection through the catheter lumen. This allows for the
delivery of any number of therapeutic devices for recan-
Fig 2. The Wildcat consists of the distal tip, catheter s
Table II. Baseline demographics (intent to treat)
Demographic
Age in years (mean  SD) (min, max)
Male (%)
Hispanic (%)
White (%)
Weight (lb) (mean  SD) (min, max) [42.5%,
Smokers (%)
Diabetes (%)
Hypertension (%)
Myocardial infarction (%)
Coronary artery bypass graft (%)
Previous percutaneous coronary intervention (%)
Other peripheral intervention (%)
NA, Not applicable; SD, standard deviation.alization and revascularization. sAt the time of the CONNECT Study, the Wildcat
evice was commercially available for use as a guidewire
and proximal handle allowing for device manipulation.
n  88 Confidence intervals
.5  11.1 (88) (33, 94) NA
53.4% (47/88) (42.5%, 64.1%)
9.1% (8/88) (4.0%, 17.1%)
85.2% (75/88) (76.1%, 91.9%)
] 174.0  44.6 (88) (61.5, 363.8) (164.7, 183.4)
80.7% (71/88) (70.9%, 88.3%)
45.5% (40/88) (34.8%, 56.4%)
86.4% (76/88) (77.4%, 92.8%)
19.3% (17/88) (11.7%, 29.1%)
20.5% (18/88) (12.6%, 30.4%)
20.5% (18/88) (12.6%, 30.4%)
38.6% (34/88) (28.4%, 49.6%)
able III. Procedural information
rocedural information
umber of patients enrolled (intent to treat) 88
umber of patients treated with Wildcat after guidewire
crossing failure (per protocol)a 84
verage number of devices used per patient (per protocol)a 1.10
rocedural timeb (intent to treat) n  88
verage guidewire time (minutes) 4.6  3.3 (88)
4.0 (0.0, 15.0)
verage Wildcat time (minutes)c 22.1  20.2 (87)
16.0 (2.0, 114.0)
verage Wildcat attempts 1.3  0.6 (88)
1.0 (1.0, 4.0)
rocedural outcomes (intent to treat) n  88
one 8.0% (7/88)
therectomy 71.6% (63/88)
ngioplasty 89.8% (79/88)
tent placement 34.1% (30/88)
aser ablation 11.4% (10/88)
ther therapy 3.4% (3/88)
Four patients were not treated per protocol, as the guidewire crossed through the
arget lesion prior toWildcat crossing. These patients were excluded per protocol.
Continuous variables expressed as mean  standard deviation (N) and
edian (min, max).
One patient did not have a reported stop time for Wildcat. Not captured in
edical records by site.69
64.1%upport catheter in conjunction with standard endovascular
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December 20121618 Pigott et aldevices and fluoroscopic guidance. The Investigational De-
vice Exemption proposed indication for use of the Wildcat
differed from its current indication as a guidewire support
catheter to a primary crossing modality via channel creation
in totally occluded peripheral vessels.
Interventional procedure. Investigators were in-
structed to make an initial attempt to access and cross the
CTO using conventional guidewires prior to use of the
Wildcat. To ensure time efficiency and minimize vessel
trauma, these attempts were to be limited to10 minutes.
If the CTO was successfully crossed using a conventional
guidewire, the Wildcat was not to be used, and the subject
would be considered a failure and would not be included in
the efficacy analysis.
Following a failed attempt to access and cross the lesion
with a conventional guidewire, the investigator proceeded
to deploy the Wildcat device. If the CTO was crossed
successfully (confirmed by angiographic evidence of the
guidewire in the distal true lumen), patients were treated
per the investigator’s choice of U.S. FDA-cleared therapeu-
tic devices. Reentry devices were permitted to regain true
lumen if the Wildcat had progressed to or immediately
distal to the distal target vessel reconstitution point.
Statistical analysis plan. Clinical data published on
several CTO crossing devices were reviewed and success
rates averaged.8-13 The averaged success rate from these
studies (weighted by total number of CTOs) is 83.7%,
which is used as the historical control rate for CONNECT.
Using a noninferiority margin of 15%, the hypothesis of the
primary efficacy end point is 68.7%. The average rate of
MAEs in the published data is 4.7%. Using this rate as the
historical control with a delta of noninferiority margin of
8.3% for the safety end points, the hypothesis for Wildcat
safety is 13.0%. A sample size of 88 is needed with actual
power of 92% for the efficacy and 83% for the safety end
points (considering a 10% loss of follow-up).
Efficacy end points were structured for a per-protocol
population; safety end points were structured for both
intent-to-treat and per-protocol populations. The safety
events rate was calculated along with a 95% upper bound
using the exact binomial method for both groups. Descrip-
tive data are presented as mean  standard error. Evalua-
tion of safety and efficacy at individual sites was conducted
using Fisher exact test to RxC tables for poolability analysis,
and a value of P  .05 was considered statistically signifi-
cant. The exact binomial method (Clopper-Pearson
method) was used when appropriate for calculation of
lower and upper bounds for end point analysis.
RESULTS
Between August 31, 2010 and March 10, 2011, 88
patients were enrolled into CONNECT, and 84 (95%)
were treated per protocol with theWildcat device following
conventional guidewire failure. Efficacy of the device was
high, as successful CTO crossing was reported and con-
firmed by independent review in 89% (75/84) of per-
protocol patients. mAngiographic review revealed that in four of 88 cases,
he investigator deployed theWildcat following a successful
nitial crossing with a conventional guidewire. These cases
re reported as screen failures per protocol and are therefore
xcluded from the efficacy analysis.
The Wildcat demonstrated a high safety profile, as no
atient experienced an in-hospital or periprocedural MAE;
owever, four patients had clinically significant perfora-
ions. The safety event rate per protocol was 4.8% (4/84)
nd 4.5% (4/88) for intent to treat. Complete patient
emographic information is shown in Table II.
Secondary end point outcomes of device, lesion, and
rocedure success were 89.3%, 89.8%, and 89.3%, respec-
ively. The mean procedural time was 123.8 minutes, and
verage fluoroscopic time was 30.2 minutes. Mean contrast
olume was 247.51 mL. Other procedural data are shown in
able III.
The majority of lesions were de novo with moderate
alcification confirmed via angiography. Mean lesion
ength by visual estimate was 174  96 mm (range, 150-
50 mm), and mean vessel diameter was 5.1  0.8 mm
range, 3.0-7.0 mm). The superficial femoral artery was the
ite for the majority of the target CTOs (85.2%). Details of
aseline lesion characteristics are shown in Table IV. De-
ice, lesion, and procedural success were high (89%) and
onsistent with the primary efficacy data.
Approximately one-third of the patients at baseline
35.3%) had measured ABIs historically suggestive of inter-
ittent claudication (0.6). Postprocedure follow-up saw
resolving ABI index, where only 7.6% of patients re-
able IV. Baseline lesion characteristics (intent to treat)
esion characteristics n  88
esion length (mm) (mean  SD) 174  96 (88)
(range, 15-350)
essel diameter (mm) (mean  SD) 5.1  0.8 (88)
(range, 3.0-7.0)
esion type
De novo 88.6% (78/88)
Restenotic 11.4% (10/88)
essel location
Superficial femoral artery 85.2% (75/88)
Popliteal 10.2% (9/88)
Superficial femoral artery/popliteal 4.5% (4/88)
alcification
None 14.8% (13/88)
Mild 30.7% (27/88)
Moderate 53.4% (47/88)
Severe 1.1% (1/88)
istal run-off vessels
0 6.8% (6/88)
1 24.0% (21/88)
2 34.1% (30/88)
3 35.2% (31/88)
otal occlusion shape
Blunt 43.2% (38/88)
Central 12.5% (11/88)
Eccentric 36.4% (32/88)
Other 8.0% (7/88)ained with a classification appropriate for intermittent
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Volume 56, Number 6 Pigott et al 1619claudication at 30 days after the intervention. Likewise,
whenmeasuring critical limb ischemia indexes (ABI 0.4),
we saw a decline in prevalence from 10.6% to 1.3% post-
intervention (Table V). With Rutherford classifications, the
majority of patients were classified as having severe claudi-
cation (51.1%) at baseline and returned to mild or asymp-
tomatic claudication by 30-day follow-up (Table V).
A reentry device (Outback, Cordis Corp, Bridgewater,
NJ) was used in 15 interventions but resulted in true lumen
access in only 12. Of the 75 patients successfully crossed, 16%
(12/75) benefited from the use of a reentry device (14.3%
[12/84] if expressed in regard to the total number of patients
enrolled). Therefore, in the majority of cases, the Wildcat is
predictable in crossing through to the distal lumen.
The upper 95% confidence bounds for the intent-to-
treat and per-protocol safety event rates were 10.1% and
10.6%, respectively (Table VI). These upper bounds were
well below the overall safety performance goal of 13.0%.
The final analysis of primary efficacy and safety data is
summarized in Table VII.
DISCUSSION
Endovascular techniques of treating lower extremity PAD
have continued to improve in recent years, allowing interven-
tionalists to shift from traditional surgical bypass to endovas-
cular treatment as the initial approach to complex lesions,
particularly in patients deemed at high risk for surgery.1,15
Patients with severe comorbidities who cannot undergo open
surgery may be able to tolerate multiple endovascular tech-
niques to maintain lower extremity patency.
Crossing femoropopliteal CTOs remains particularly
Table V. Ankle-brachial indexes (ABIs) and Rutherford cl
ABIa Baselin
(intent to treat) (n  8
ABI 1.3: Vessel hardening from
peripheral arterial disease 2.40% (2
ABI 0.95: Normal range 14.1% (1
ABI 0.95: Mild arterial disease 37.6% (3
ABI 0.6: Intermittent claudication 35.3% (3
ABI 0.4: Critical limb ischemia 10.60% (9
Rutherfordb classification Baseline
(intent to treat) (n  88)
0 - Asymptomatic 1.10% (1/8
I - Mild claudication 1.10% (1/8
I - Moderate claudication 14.80% (13/
I - Severe claudication 51.10% (45/
II - Ischemic rest pain 25.00% (22/
II - Minor tissue loss 6.80% (6/8
III - Major tissue loss 0% (0/8
NA, Not applicable.
aABI values are reported for target vessel side only. Baseline and postproced
completed per protocol. Missing follow-up data are due to six patients being
to a below-the-knee amputation; one patient declined ABI testing; one patie
ABI was not obtained.
bTwo patients did not have Rutherford assessments at follow-up: One patien
and assessment was not completed verbally.challenging, especially if the proximal cap of the occluded Gegment cannot be engaged or crossed with conventional
uidewire techniques. The ability to successfully cross these
esions is directly related to acute procedural success and
ong-term outcomes. Several catheters have been developed
ithin the past decade to improve upon the crossing success
ates observed with standard guidewire techniques.
The Cordis Frontrunner (Cordis Corp, Miami, Fla) is
esigned to cross resistant CTOs using controlled blunt
icrodissection. Mossop et al13 reported on a series of 36
atients with 44 symptomatic CTOs that had previously
ailed conventional attempts at revascularization. Proce-
ural success was achieved in 40 (91%) cases, 14 (35%) of
hich required guidewire redirection using a true lumen
eentry catheter.
The Crosser CTO Recanalization System (Flowcardia
nc, Sunnyvale, Calif) uses high-frequency vibrational en-
rgy to disrupt and channel through occluded plaque.
able VI. Primary safety end point per protocol
rimary safety (per protocol) n  84
verall safety events 4.8% (4/84)
ajor adverse eventa 0.0% (0/84)
Death 0.0% (0/84)
Unplanned major amputation 0.0% (0/84)
Emergent target vessel revascularization 0.0% (0/84)
linically significant perforationb 4.8% (4/84)
linically significant embolizationb 0.0% (0/84)
rade C dissectionb 0.0% (0/84)
Investigator assessment.
Angiographic reviewer assessment.
cations
Postprocedure 30 days
(n  88) (n  88)
2.40% (2/83) 11.40% (9/79)
) 44.60% (37/83) 53.20% (42/79)
) 36.10% (30/83) 26.60% (21/79)
) 12.00% (10/83) 7.60% (6/79)
4.80% (4/83) 1.30% (1/79)
Postprocedure
30 days
(n  88)
NA 38.40% (33/86)
NA 33.70% (29/86)
NA 15.10% (13/86)
NA 7.00% (6/86)
NA 3.50% (3/86)
NA 1.20% (1/86)
NA 1.20% (1/86)
issing data are due to either not being able to calculate ABI or to not being
ed by phone instead of in-office visits. One patient’s ABI was not done due
in a rehabilitation facility and the ABI was not performed; and one patient’s
n rehabilitation at time of follow-up, and one patient was followed by phoneassifi
e
8)
/85)
2/85
2/85
0/85
/85)
8)
8)
88)
88)
88)
8)
8)
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December 20121620 Pigott et aldiabetic patients with critical limb ischemia who had resis-
tant lower extremity CTOs. The Crosser device successfully
crossed nine (75%) of the lesions intraluminally with no
perforation or dissection in the recanalized vessels. An early
report of vibrational angioplasty using coronary equipment
described complete success and no complications in six
patients with femoropopliteal lesions.14
Some CTO devices use imaging capabilities to reenter
the true lumen. Saket et al11 reported on the CrossPoint
TransAccess catheter (Medtronic Inc, Santa Rosa, Calif),
which includes an IVUS transducer to achieve controlled
lumen reentry, in seven patients undergoing subintimal
angioplasty for CTOs. Antegrade flow was restored in all
patients with no reported complications. In 8 months of
follow-up, all patients were symptom free.
Visualizing CTOs with optical coherence reflectometry
was demonstrated in reports by Kirvaitis et al,9,10 using the
Safe-Cross Radio Frequency System (Kensey Nash Corp,
Exton, Pa). In 72 patients with 75 peripheral CTOs, the
authors reported a 76% crossing rate with no clinical perfo-
rations or distal embolizations. Pulsed laser was another
technology incorporated into a crossing device; the
CliRpath Excimer Laser system (Spectranetics Corp, Colo-
rado Springs, Colo) was used in 318 consecutive patients
with 411 superficial femoral artery CTOs averaging 19.4
6 cm in length.8 The authors reported an initial success rate
of 83% and a 1-year primary patency of 37%.
The results of CONNECT compare favorably with the
outcomes reported in these other CTO crossing catheter
papers. The Wildcat demonstrated a successful primary
safety and efficacy profile. Significantly, there were no
deaths, no emergent target vessel revascularization, and no
unplanned target limb major amputations. There were,
however, four clinically significant perforations recorded.
The operator noted one of these at the time of the proce-
dure; the core laboratory noted the remaining three later.
No rescue or remedial interventions were required for any
of these events. Moreover, no embolization, distal ischemic
events, or significant dissections were reported.
The device exceeded the required crossing rate profile
with successful crossing noted in 89.3% (75/84) of patients
on a per-protocol basis. It is important to reiterate, how-
ever, that study inclusion criteria required that all patients
undergo an initial CTO crossing attempt using a conven-
tional guidewire. If crossing was successful at this initial
attempt, these patients were excluded from study enroll-
ment. Therefore, the patients enrolled per protocol repre-
sent a more challenging subset of femoropopliteal CTO
Table VII. Overall primary safety and efficacy end points
Primary end point Value
Primary safety events (n  84) (per protocol) 4.8% (4/8
Primary safety events (n  88) (intent to treat) 4.5% (4/8
Primary efficacy (n  84) (per protocol) 89.3% (75/cases. MIt should be noted that in this study, the Wildcat
atheter was evaluated as a CTO crossing catheter, not as a
eentry catheter. Reentry devices were permitted to regain
rue lumen if the Wildcat had progressed to or immediately
istal to the distal target vessel reconstitution point. Even if
he 12 procedures benefiting from the use of a reentry
atheter were counted as failures of successful crossing, the
rimary efficacy end points (performance goal 68.7%)
ould have been surpassed.
A review of the target lesions reveals that these pre-
ented a significant challenge in that the average lesion
ength was approximately 17.5 cm, and more than half of
he CTOs were noted to contain at least “moderate” calci-
cation (Table IV). Increasing lesion length and severity of
alcification are criteria reported to adversely affect CTO
rossing rates as well as procedural patency.16,17 The pre-
onderance of the superficial femoral artery lesion location
85.2%) may relate to the high level of smoking (80.7%) in
his study population (Table II).
Although this study demonstrates the safety and effi-
acy of the Wildcat to cross femoropopliteal CTOs, further
nvestigation is necessary to evaluate whether “true lumen”
rossing creates a difference in long-term procedural suc-
ess or limb salvage rates. Future studies of intraluminal
rossing compared with other techniques such as subinti-
al angioplasty are needed but likely will require the use of
ore sophisticated vessel and lesion imaging. IVUS or
ptical coherence technology imaging would ensure that
ppropriate comparisons are made to identify that a true
ntraluminal or subintimal channel was utilized.18
ONCLUSIONS
In the CONNECT study, the Wildcat catheter sur-
assed primary safety and efficacy end points in crossing
ifficult femoropopliteal CTOs. This device offers an addi-
ional option to interventionalists in the treatment of chal-
enging lower extremity peripheral arterial occlusions.
ased on the results of this trial, the Wildcat was recently
iven U.S. FDA clearance as a CTO crossing catheter.
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